2023 Journal Article Management of high and low risk malignant polyps – a population wide analysisZammit, Andrew P., Panahi, Seyed E., Brown, Ian, Hooper, John D., Clark, David A. and Riddell, Andrew D. (2023). Management of high and low risk malignant polyps – a population wide analysis. Colorectal Disease, 25 (1), 66-74. doi: 10.1111/codi.16328 |
2022 Journal Article CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitorsLu, Xue, He, Yaowu, Johnston, Rebecca L., Nanayakarra, Devathri, Sankarasubramanian, Sivanandhini, Lopez, J. Alejandro, Friedlander, Michael, Kalimutho, Murugan, Hooper, John D., Raninga, Prahlad V. and Khanna, Kum Kum (2022). CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors. Journal of Experimental and Clinical Cancer Research, 41 (1) 355, 1-17. doi: 10.1186/s13046-022-02570-4 |
2022 Conference Publication Development of antibody-drug conjugates targeting the CDCP1 receptor for the treatment of Triple negative and metastatic breast cancerGough, M., Kwah, K., Khan, T., He, Y., Pyke, C., Ratnayake, G., Snell, C., Hooper, J. and Kryza, T. (2022). Development of antibody-drug conjugates targeting the CDCP1 receptor for the treatment of Triple negative and metastatic breast cancer. 13th European Breast Cancer Conference (EBCC-13), Barcelona, Spain, 16-18 November 2022. Oxford, United Kingdom: Elsevier. doi: 10.1016/s0959-8049(22)01571-4 |
2022 Journal Article Timing of surveillance colonoscopy following malignant colorectal polypectomy in QueenslandZammit, Andrew P., Brown, Ian, Hooper, John D., Clark, David A. and Riddell, Andrew D. (2022). Timing of surveillance colonoscopy following malignant colorectal polypectomy in Queensland. ANZ Journal of Surgery, 93 (3), 606-611. doi: 10.1111/ans.18069 |
2022 Journal Article CUB Domain-Containing Protein 1 (CDCP1) is a rational target for the development of imaging tracers and antibody-drug conjugates for cancer detection and therapyKhan, Tashbib, Lyons, Nicholas J., Gough, Madeline, Kwah, Kayden K.X., Cuda, Tahleesa J., Snell, Cameron E., Tse, Brian W., Sokolowski, Kamil A., Pearce, Lesley A., Adams, Timothy E., Rose, Stephen E., Puttick, Simon, Pajic, Marina, Adams, Mark N., He, Yaowu, Hooper, John D. and Kryza, Thomas (2022). CUB Domain-Containing Protein 1 (CDCP1) is a rational target for the development of imaging tracers and antibody-drug conjugates for cancer detection and therapy. Theranostics, 12 (16), 6915-6930. doi: 10.7150/thno.78171 |
2022 Conference Publication EP-369 examining EphA2 expression in colorectal cancerLyons, Nicholas, Hooper, John, Kryza, Thomas, Clark, David and Riddell, Andrew (2022). EP-369 examining EphA2 expression in colorectal cancer. Association of Surgeons of Great Britain and Ireland Annual Congress, Liverpool, United Kingdom, 2022. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/bjs/znac245.094 |
2022 Conference Publication Intraoperative identification of colorectal cancer lesions using indocyanine green labelled antibodies in preclinical murine modelsLyons, Nicholas, Hooper, John, Clark, David, Riddell, Andrew and Kryza, Thomas (2022). Intraoperative identification of colorectal cancer lesions using indocyanine green labelled antibodies in preclinical murine models. Association of Surgeons of Great Britain and Ireland, Annual Congress, Liverpool, United Kingdom, 3-5 May 2022. Oxford, United Kingdom: Oxford University Press . doi: 10.1093/bjs/znac245.093 |
2022 Journal Article A population‐based study of the management of rectal malignant polyps and the use of trans‐anal surgeryZammit, Andrew P., Brown, Ian, Hooper, John D., Clark, David A. and Riddell, Andrew D. (2022). A population‐based study of the management of rectal malignant polyps and the use of trans‐anal surgery. ANZ Journal of Surgery, 92 (11), 2949-2955. doi: 10.1111/ans.17917 |
2022 Journal Article Protease‐activated receptor‐2 dependent and independent responses of bone cells to prostate cancer cell secretory productsPagel, Charles N., Kularathna, Pamu K., Sanaei, Reza, Young, Neil D., Hooper, John D. and Mackie, Eleanor J. (2022). Protease‐activated receptor‐2 dependent and independent responses of bone cells to prostate cancer cell secretory products. The Prostate, 82 (6), 723-739. doi: 10.1002/pros.24316 |
2022 Journal Article Erratum: Alpha-Tomatine Attenuation of In Vivo Growth of Subcutaneous and Orthotopic Xenograft Tumors of Human Prostate Carcinoma PC-3 Cells Is Accompanied by Inactivation of Nuclear Factor-Kappa B Signaling (PLoS ONE (2013) 8:2 (e57708) DOI: 10.1371/journal.pone.0057708)Lee, Sui-Ting, Wong, Pooi-Fong, He, Hui, Hooper, John David and Mustafa, Mohd Rais (2022). Erratum: Alpha-Tomatine Attenuation of In Vivo Growth of Subcutaneous and Orthotopic Xenograft Tumors of Human Prostate Carcinoma PC-3 Cells Is Accompanied by Inactivation of Nuclear Factor-Kappa B Signaling (PLoS ONE (2013) 8:2 (e57708) DOI: 10.1371/journal.pone.0057708). PLoS ONE, 17 (5 May) e0268234. doi: 10.1371/journal.pone.0268234 |
2022 Journal Article Patient and pathological predictors of management strategy for malignant polyps following polypectomy: a systematic review and meta-analysisZammit, Andrew P., Lyons, Nicholas J., Chatfield, Mark D., Hooper, John D., Brown, Ian, Clark, David A. and Riddell, Andrew D. (2022). Patient and pathological predictors of management strategy for malignant polyps following polypectomy: a systematic review and meta-analysis. International Journal of Colorectal Disease, 37 (5), 1035-1047. doi: 10.1007/s00384-022-04142-6 |
2021 Journal Article Protease-activated receptor-2 promotes osteogenesis in skeletal mesenchymal stem cells at the expense of adipogenesis: involvement of interleukin-6Sanaei, R., Kularathna, P. K., Taghavi, N., Hooper, J. D., Pagel, C. N. and Mackie, E. J. (2021). Protease-activated receptor-2 promotes osteogenesis in skeletal mesenchymal stem cells at the expense of adipogenesis: involvement of interleukin-6. Bone Reports, 15 101113, 101113. doi: 10.1016/j.bonr.2021.101113 |
2021 Journal Article Elevating CDCA3 levels enhances tyrosine kinase inhibitor sensitivity in TKI-resistant EGFR mutant non-small-cell lung cancerSahin, Katherine B., Shah, Esha T., Ferguson, Genevieve P., Molloy, Christopher, Kalita-de Croft, Priyakshi, Hayes, Sarah A., Hudson, Amanda, Colvin, Emily, Kamitakahara, Hannah, Harvie, Rozelle, Hasovits, Csilla, Khan, Tashbib, Duijf, Pascal H. G., Howell, Viive M., He, Yaowu, Bolderson, Emma, Hooper, John D., Lakhani, Sunil R., Richard, Derek J., O’Byrne, Kenneth J. and Adams, Mark N. (2021). Elevating CDCA3 levels enhances tyrosine kinase inhibitor sensitivity in TKI-resistant EGFR mutant non-small-cell lung cancer. Cancers, 13 (18) 4651, 4651. doi: 10.3390/cancers13184651 |
2021 Journal Article Preclinical molecular PET-CT imaging targeting CDCP1 in colorectal cancerCuda, Tahleesa J., He, Yaowu, Kryza, Thomas, Khan, Tashbib, Tse, Brian W., Sokolowski, Kamil A., Liu, Cheng, Lyons, Nicholas, Gough, Madeline, Snell, Cameron E., Wyld, David K., Rose, Stephen, Riddell, Andrew D., Stevenson, Andrew R. L., Thomas, Paul A., Clark, David A., Puttick, Simon and Hooper, John D. (2021). Preclinical molecular PET-CT imaging targeting CDCP1 in colorectal cancer. Contrast Media and Molecular Imaging, 2021 3153278, 3153278. doi: 10.1155/2021/3153278 |
2021 Journal Article Preclinical Evaluation of a Fluorescent Probe Targeting Receptor CDCP1 for Identification of Ovarian CancerHe, Yaowu, Khan, Tashbib, Kryza, Thomas, Jones, Martina L., Goh, Justin B., Lyons, Nicholas J., Pearce, Lesley A., Lee, Michael D, Gough, Madeline, Rogers, Rebecca, Davies, Claire M,, Gilks, C. Blake, Hodgkinson, Thomas, Lourie, Rohan, Barry, Sinead C., Perrin, Lewis C., Williams, Charlotte C., Puttick, Simon, Adams, Timothy E., Munro, Trent P., Hooper, John D. and Chetty, Naven (2021). Preclinical Evaluation of a Fluorescent Probe Targeting Receptor CDCP1 for Identification of Ovarian Cancer. Molecular Pharmaceutics, 18 (9) acs.molpharmaceut.1c00401, 3464-3474. doi: 10.1021/acs.molpharmaceut.1c00401 |
2021 Journal Article Extracellular vesicle transmission of chemoresistance to ovarian cancer cells is associated with hypoxia-induced expression of glycolytic pathway proteins, and prediction of epithelial ovarian cancer disease recurrenceAlharbi, Mona, Lai, Andrew, Sharma, Shayna, Kalita-De Croft, Priyakshi, Godbole, Nihar, Campos, America, Guanzon, Dominic, Salas-Burgos, Alexis, Carrion, Flavio, Zuñiga, Felipe A., Perrin, Lewis, He, Yaowu, Pejovic, Tanja, Winters, Carmen, Morgan, Terry, Hooper, John D., Rice, Gregory E. and Salomon, Carlos (2021). Extracellular vesicle transmission of chemoresistance to ovarian cancer cells is associated with hypoxia-induced expression of glycolytic pathway proteins, and prediction of epithelial ovarian cancer disease recurrence. Cancers, 13 (14) 3388, 1-26. doi: 10.3390/cancers13143388 |
2021 Journal Article Substrate-biased activity-based probes identify proteases that cleave receptor CDCP1Kryza, Thomas, Khan, Tashbib, Lovell, Scott, Harrington, Brittney S., Yin, Julia, Porazinski, Sean, Pajic, Marina, Koistinen, Hannu, Rantala, Juha K., Dreyer, Tobias, Magdolen, Viktor, Reuning, Ute, He, Yaowu, Tate, Edward W. and Hooper, John D. (2021). Substrate-biased activity-based probes identify proteases that cleave receptor CDCP1. Nature Chemical Biology, 17 (7), 776-783. doi: 10.1038/s41589-021-00783-w |
2021 Journal Article The CDCP1 signalling hub: a target for cancer detection and therapeutic interventionKhan, Tashbib, Kryza, Thomas, Lyons, Nicholas J., He, Yaowu and Hooper, John D. (2021). The CDCP1 signalling hub: a target for cancer detection and therapeutic intervention. Cancer Research, 81 (9) canres.2978.2020, QF1-QF11. doi: 10.1158/0008-5472.can-20-2978 |
2021 Journal Article Histone modifying enzymes in gynaecological cancersRamarao-Milne, Priya, Kondrashova, Olga, Barry, Sinead, Hooper, John D., Lee, Jason S. and Waddell, Nicola (2021). Histone modifying enzymes in gynaecological cancers. Cancers, 13 (4) 816, 1-21. doi: 10.3390/cancers13040816 |
2021 Journal Article A nucleotide analog prevents colitis associated cancer via Β-catenin independently of inflammation and autophagySheng, Yong Hua, Giri, Rabina, Davies, Julie, Schreiber, Veronika, Alabbas, Saleh, Movva, Ramya, He, Yaowu, Wu, Andy, Hooper, John, McWhinney, Brett, Oancea, Iulia, Kijanka, Gregor, Hasnain, Sumaira, Lucke, Andrew J., Fairlie, David P., McGuckin, Michael A., Florin, Timothy H. and Begun, Jakob (2021). A nucleotide analog prevents colitis associated cancer via Β-catenin independently of inflammation and autophagy. Cellular and Molecular Gastroenterology and Hepatology, 11 (1), 33-53. doi: 10.1016/j.jcmgh.2020.05.012 |